Sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor, has recently been evaluated in two trials of patients with T2DM: the Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening HF (SOLOIST-WHF) trial [154,155]. Here, SLC5A2 is linked to type 2 diabetes mellitus.